Claims
- 1. A purified peptide comprising the amino acid sequence (I): Xaa1Xaa2Xaa3Xaa4Xaa5Cys6Cys7Xaa8Xaa9Cys10Cys11Xaa12Xaa13Xaa14Cys15Xaa16Xaa17Cys18Xaa1Xaa20Xaa21 (SEQ ID NO:119) wherein: Xaa1Xaa2Xaa3Xaa4Xaa5 is Asn Ser Ser Asn Tyr (SEQ ID NO:121 )or is missing or Xaa1Xaa2Xaa3Xaa4 is missing.
- 2. The purified peptide of claim 1 wherein Xaa5 is Asn, Trp, Tyr, Asp, or Phe.
- 3. The purified peptide of claim 1 wherein Xaa5 is Thr or Ile.
- 4. The purified peptide of claim 1 wherein Xaa5 is Tyr, Asp or Trp.
- 5. The purified peptide of claim 1 wherein Xaa8 is Glu, Asp, Gln, Gly or Pro.
- 6. The purified peptide of claim 1 wherein Xaa9 is Leu, Ile, Val, Ala, Lys, Arg, Trp, Tyr or Phe.
- 7. The purified peptide of claim 1 wherein Xaa9 is Leu, Ile, Val, Lys, Arg, Trp, Tyr or Phe.
- 8. The purified peptide of claim 1 wherein Xaa12 is Asn, Tyr, Asp or Ala.
- 9. The purified peptide of claim 1 wherein Xaa13 is Ala, Pro or Gly.
- 10. The purified peptide of claim 1 wherein Xaa14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile, Leu, Lys, Arg, or Asp.
- 11. The purified peptide of claim 1 wherein Xaa16 is Thr, Ala, Asn, Lys, Arg, Trp.
- 12. The purified peptide of claim 1 wherein Xaa17 is Gly, Pro or Ala.
- 13. The purified peptide of claim 1 wherein Xaa19 is Trp, Tyr, Phe, Asn or Leu.
- 14. The purified peptide of claim 1 wherein Xaa19 is Lys or Arg.
- 15. The purified peptide of claim 1 wherein Xaa20 Xaa21 is AspPhe or Xaa20 is Asn or Glu and Xaa21 is missing.
- 16. A purified peptide comprising the amino acid sequence:
- 17. A purified peptide comprising the amino acid sequence:
- 18. A purified peptide consisting of the amino acid sequence:
- 19. A purified peptide consisting of the amino acid sequence:
- 20. A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
- 21. A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
- 22. A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
- 23. A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
- 24. A purified polypeptide comprising an amino acid sequence of any of:
- 25. A method for treating a gastrointestinal disorder in a patient comprising administering the peptide of claim 1.
- 26. A method for treating a gastrointestinal disorder in a patient comprising administering the peptide of claim 24.
- 27. The method of any of claims 20-26 wherein the gastrointestinal disorder is a gastrointestinal motility disorder.
- 28. The method of any of claims 20-26 wherein the gastrointestinal disorder is selected from the group consisting of a gastrointestinal motility disorder, irritable bowel syndrome, chronic constipation, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
- 29. A method for treating obesity comprising administering the peptide of any of claims 1, 16-19, and 24.
- 30. A method for treating congestive heart failure comprising administering the peptide of any of claims 1, 16-19, and 24.
- 31. A method for treating benign prostatic hyperplasia comprising administering the peptide of any of claims 1, 16-19, and 24.
- 32. The purified peptide of any of claims 1, 16, 17, and 24 wherein the polypeptide comprises the amino acid sequence DF; QHNPR (SEQ ID NO:111); VQHNPR (SEQ ID NO:112); VRQHNPR (SEQ ID NO:113); VRGQHNPR (SEQ ID NO:114); VRGPQHNPR (SEQ ID NO:115); VRGPRQHNPR (SEQ ID NO:116); VRGPRRQHNPR (SEQ ID NO:117); or RQHNPR (SEQ ID NO:118) fused to its amino terminus or its caboxy terminus.
- 33. The purified peptide of any of claims 1, 16, 17, and 24 wherein the purified polypeptide comprises the amino acid sequence of an analgesic peptide selected from the group consisting of endomorphin-1, endomorphin-2, nocistatin, dalargin, lupron, and substance P fused to its amino terminus or its carboxy terminus.
- 34. The purified peptide of any of claims 1, 16, 17, and 24 wherein the polypeptide includes no more than 10 additional amino acids at its amino terminus or carboxy terminus or both and wherein the polypeptide is a guanylate cyclase receptor agonist.
- 35. The purified peptide of claim 1 wherein wherein: Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 is missing; Xaa8 is Glu; Xaa9 is Leu, Ile, Lys, Arg, Trp, Tyr or Phe; Xaa12 is Asn; Xaa13 is Pro; Xaa14 is Ala; Xaa16 is Thr, Ala, Lys, Arg, Trp; Xaa17 is Gly; Xaa19 is Tyr or Leu; and Xaa20 Xaa21 is AspPhe or is missing.
- 36. A method for treating a patient suffering from constipation, the method comprising administering the polypeptide of any of claims 1, 16-23 and 28.
- 37. A method for increasing the activity of an intestinal guanylate cyclase (GC—C) receptor in a patient, the method comprising administering the polypeptide of any of claims 1, 16-19 and 24.
- 38. A method for treating a gastrointestinal disorder in a patient comprising administering a GC—C receptor agonist.
- 39. The method of claim 38 wherein the gastrointestinal disorder is a gastrointestinal motility disorder.
- 40. The method of claim 38 wherein the gastrointestinal disorder is selected from the group consisting of a gastrointestinal motility disorder, irritable bowel syndrome, chronic constipation, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
- 41. A method for treating obesity comprising administering a GC—C receptor agonist.
- 42. A method for treating congestive heart failure comprising administering a GC—C receptor agonist.
- 43. A method for treating benign prostatic hyperplasia comprising administering a GC—C receptor agonist.
- 44. A method for treating visceral pain comprising administering a GC—C receptor agonist.
- 45. A method for treating inflammation comprising administering a GC—C receptor agonist.
- 46. A method for treating constipation comprising administering a GC—C receptor agonist.
- 47. A method for treating visceral pain comprising administering the polypeptide of any of claims 1, 16-19 and 24.
- 48. A method for treating inflammation comprising administering the polypeptide of any of claims 1, 16-19 and 24.
- 49. A method for treating cystic fibrosis comprising administering the polypeptide of any of claims 1, 16-19 and 24.
- 50. A method for treating cystic fibrosis comprising administering a GC—C receptor agonist.
- 51. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24 and a pharmaceutically acceptable carrier.
- 52. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24 surrounded by an enteric coating.
- 53. A controlled release pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24 and a biodegradable polymeric matrix.
- 54. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24, an analgesic agent and a pharmaceutically acceptable carrier.
- 55. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24, a phosphodiesterase inhibitor and a pharmaceutically acceptable carrier.
- 56. A method for treating cancer, a respiratory disorder, a neurological disorder, a disorder associated with fluid and sodium retention, a disorder associated with carbonate imbalance, erectile dysfunction, an insulin-related disorder, or an inner ear disorder, the method comprising administering the peptide of any of claims 1, 16-19 and 24.
- 57. A method for treating cancer, a respiratory disorder, a neurological disorder, a disorder associated with fluid and sodium retention, a disorder associated with carbonate imbalance, erectile dysfunction, an insulin-related disorder, or an inner ear disorder, the method comprising administering a GC—C receptor agonist.
- 58. A method of producing the peptide of any of claims 16-19 and 24, comprising providing a cell harboring a nucleic acid molecule encoding the polypeptide, culturing the cell under conditions in which the peptide is expressed, and isolating the expressed peptide.
- 59. A method of producing the peptide of any of claims 16-19 and 24, comprising chemically synthesizing the peptide and they purifying the synthesized peptide.
- 60. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24 and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
- 61. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24 and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
- 62. A pharmaceutical composition comprising the peptide of any of claims 1, 16-19 and 24 and gut hormone fragment peptide YY3-36, glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-β-methylbutyrate, or pyruvate.
- 63. A pharmaceutical composition comprising a GC—C receptor agonist and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
- 64. A pharmaceutical composition comprising a GC—C receptor agonist and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
- 65. A pharmaceutical composition comprising a GC—C receptor agonist and gut hormone fragment peptide YY3-36, glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-,-methylbutyrate, or pyruvate.
- 66. A method for treating congestive heart failure comprising administering the peptide of any of claims 1, 16-19 and 24 and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
- 67. A method for treating benign prostatic hyperplasia comprising administering the peptide of any of claims 1, 16-19 and 24 and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
- 68. A method for treating obesity comprising administering the peptide of any of claims 1, 16-19 and 24 and gut hormone fragment peptide YY3-36, glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-β-methylbutyrate, or pyruvate.
- 69. A method for treating congestive heart failure comprising administering a GC—C receptor agonist and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
- 70. A method for treating benign prostatic hyperplasia comprising a GC—C receptor agonist and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
- 71. A method for treating obesity comprising administering a GC—C receptor agonist and gut hormone fragment peptide YY3-36, glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-β-methylbutyrate, or pyruvate.
CLAIM OF PRIORITY
[0001] This application claims priority under 35 USC § 119(e) to U.S. Provisional Patent Application Ser. No. 60/443,098, filed on Jan. 28, 2003; U.S. Provisional Patent Application Ser. No. 60/471,288, filed on May 15, 2003 and U.S. Provisional Patent Application Ser. No. 60/519,460, filed on Nov. 12, 2003, the entire contents of which are hereby incorporated by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60443098 |
Jan 2003 |
US |
|
60471288 |
May 2003 |
US |
|
60519460 |
Nov 2003 |
US |